Genetic Analysis AS (XSAT: GEAN)
Health Care · Biotechnology · NO
Nkr0.71
+12.34% today · -14.5% 1Y
Genetic Analysis AS (XSAT: GEAN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.27M.
Over the last twelve months the share price has lost 14.5%, trading between 0.56 and 1.10.
Tweenvest scores Genetic Analysis AS across four factors: quality 44/100, value 75/100, growth 74/100. Its strongest factor is value.
GEAN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.27M
- Revenue (TTM)
- $2.21M
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- 2.09
- 52-week high
- Nkr1.10
- 52-week low
- Nkr0.56
- Avg volume (3M)
- —
- Shares outstanding
- 69.09M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.